Rigel Pharmaceuticals Inc (RIGL): Total Liabilities
$122.11M
As of 2025-12-31
$95.64M
As of 2026-06-30
-6.2%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $122.11M | -24.0% | 2026-03-03, Balance as of period end |
| 2024-12-31 | $160.69M | +10.2% | 2026-03-03, Balance as of period end |
| 2023-12-31 | $145.87M | -1.4% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $147.90M | +8.0% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $136.95M | n/a | 2023-03-07, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Rigel Pharmaceuticals Inc (RIGL) | 2025-12-31 | $122.11M | -24.0% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $27.78M | +192.2% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $334.65M | +27.5% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $465.08M | +6.5% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $37.52M | +74.3% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $54.87M | +30.6% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $161.76M | +37.5% |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | $16.69M | +20.9% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $210.17M | -7.7% |
Compare RIGL, RAPP, ARDX, SNDX side by side · Screen every company in Pharmaceutical Preparations ↗